PODCAST: Announcing Crowell & Moring’s Regulatory Forecast 2019
Client Alert | less than 1 min read | 02.28.19
On February 27, Crowell & Moring published its fifth annual Regulatory Forecast, exploring a diverse range of regulatory developments coming out of Washington and other leading regulatory centers of power.
The publication’s editors, Richard Lehfeldt and Dan Wolff, both partners in the firm’s Administrative Law and Regulatory Practice, sat down to discuss the forecast. In this 21 minute podcast, Richard and Dan discuss what you will find in our Regulatory Forecast 2019.
Click below to listen or access from the link:
SoundCloud
Contacts
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection
